Malignant Infratentorial Neoplasm — Trials

Malignant Infratentorial Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

302 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 99
Recruiting: 50
Ph III recruiting: 3
Growth YoY: —
Industry share: 9%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (46)

clinicaltrialsPublishedShowing 101–117 of 117 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01708174	A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)	completed	Phase 2	22	Novartis PharmaceuticalsINDUSTRY	13	Aug 11, 2017	clinicaltrials
NCT01125800	A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB	completed	Phase 1 / Phase 2	76	Novartis PharmaceuticalsINDUSTRY	6	Mar 20, 2017